Seroatlas · Human Serome Atlas

CEACAM5

Cell adhesion molecule CEACAM5

Also known as: CD66e, CEA, CEAM5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P06731
Gene: CEACAM5
Ensembl: ENSG00000105388
Chromosome: 19
Canonical length: 702 aa
Protein class: Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Plasma membrane
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. Additionally, the encoded protein may regulate differentiation, apoptosis, and cell polarity. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]

Canonical amino-acid sequenceUniProt

702 residues, UniProt reviewed canonical sequence.

>P06731|CEACAM5
     1  MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE VLLLVHNLPQ
    61  HLFGYSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI IYPNASLLIQ NIIQNDTGFY
   121  TLHVIKSDLV NEEATGQFRV YPELPKPSIS SNNSKPVEDK DAVAFTCEPE TQDATYLWWV
   181  NNQSLPVSPR LQLSNGNRTL TLFNVTRNDT ASYKCETQNP VSARRSDSVI LNVLYGPDAP
   241  TISPLNTSYR SGENLNLSCH AASNPPAQYS WFVNGTFQQS TQELFIPNIT VNNSGSYTCQ
   301  AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ NTTYLWWVNN
   361  QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS VDHSDPVILN VLYGPDDPTI
   421  SPSYTYYRPG VNLSLSCHAA SNPPAQYSWL IDGNIQQHTQ ELFISNITEK NSGLYTCQAN
   481  NSASGHSRTT VKTITVSAEL PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS
   541  LPVSPRLQLS NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIISP
   601  PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN GTYACFVSNL
   661  ATGRNNSIVK SITVSASGTS PGLSAGATVG IMIGVLVGVA LI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CEACAM5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 920 nTPM

Expression across tissuesHPA

Tissue

colon: 920 nTPM
rectum: 885 nTPM
esophagus: 198 nTPM
appendix: 175 nTPM
stomach: 154 nTPM
vagina: 63 nTPM

Single-cell type

colonocytes: 184 nCPM
esophageal apical cells: 144 nCPM
goblet cells: 86 nCPM
foveolar cells: 51 nCPM
alveolar cells type 1: 28 nCPM
enteric stem cells: 21 nCPM

Immune cell

basophil: 0.3 nTPM
neutrophil: 0.3 nTPM
eosinophil: 0.1 nTPM
NK-cell: 0.1 nTPM
non-classical monocyte: 0.1 nTPM
classical monocyte: 0 nTPM

Brain region

cerebellum: 1.1 nTPM
choroid plexus: 1 nTPM
cerebral cortex: 0.9 nTPM
white matter: 0.9 nTPM
hippocampal formation: 0.8 nTPM
medulla oblongata: 0.8 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CEACAM5.

Disease | ImmuneIEDB

Conditions an epitope on CEACAM5 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.99
gnomAD pLI: 0
gnomAD missense Z: 0.19
DepMap mean gene effect: -0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CEACAM5 as an antibody target. Whether an autoantibody or antibody against CEACAM5 could matter depends on whether native CEACAM5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CEACAM5 is annotated at the cell surface, where native CEACAM5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CEACAM5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...